Article Date: 15 Jun 2008 - 0:00 PDT
Opexa Therapeutics Reports Favorable Two-Year Data In Phase I/II Retreatment Studies Of Tovaxin(R) For Multiple Sclerosis
Opexa Therapeutics, Inc. a cell therapy development and commercialization company, announced favorable safety and efficacy data for Tovaxin®, the Company's investigational T-cell vaccination therapy for multiple sclerosis (MS), in the second year of open-label clinical retreatment studies in patients with MS.
The "intent to treat" population of 22 patients included 13 with relapsing remitting multiple sclerosis (RRMS) and nine with secondary progressive multiple sclerosis (SPMS). An analysis of disease progression of disability over a two year period, as measured by a 1.0 or greater change in Expanded Disability Scoring Scale (EDSS), showed that 27.3% of patients demonstrated sustained improvement, 59.1% had no disease progression and 13.6% experienced sustained worsening of disability. The improvement in the EDSS scores ranged from 1.0 to 4.5 (average 2.41). During the two-year study period 72.7% of patients remained relapse-free.